china is host to 70 percent of all car cell therapy trials registered in 2017 and the first four months of 2018 (150 out of 214).
.
.
.
.
.: "evidence for decreased calcitonin gene-related peptide (cgrp) receptors and compromised responsiveness to cgrp of fetoplacental vessels in preeclamptic pregnancies."
.
he said: "greater and immediate attention needs to be applied in these two areas."
.
.